Stock fact sheet · data as of

GoodRx Holdings, Inc. (GDRX): fair value, margin of safety and Wheel Score

Healthcare · Medical - Healthcare Information Services · United States · Blend

Close3.51
GLS fair value3.448 of 9 models
Margin of safety-2%price above fair value
Wheel Score62Fairout of 100
Health7/9Piotroski F-score
Moat4.5/10GLS 10-year score
Market cap$1.2B1.9M shares a day
Implied vol.85%near-the-money, 20-60 d
P/E73.2EPS 0.05
Dividend yieldnone
Beta1.69moves more than the market
Next earnings3 Nov 2026in 18 days (after the close)

Is GDRX undervalued?

GoodRx Holdings, Inc. (GDRX) closed at 3.51 on 16 Oct 2026, close to the GLS average fair value of 3.44 (1.8% above fair value). 3 of the 8 models that produced a number sit above the price, 5 below - the market and our models roughly agree. With little margin of safety either way, the case for or against the stock rests on the quality numbers and the option premium rather than on price.

There is a wide gap between EPV (0.5321) and 10 Cap (11.06). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.

The nightly engine files GDRX under Blend.

Nine valuation models for GDRX

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF4.95+41%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number1.43-59%The most a defensive investor pays for the earnings and book value per share
Graham Growth2.66-24%Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields
Lynch1.15-67%EPS × the earnings growth rate (PEG of 1), growth capped at 25%
GLS Growth1.74-50%EPS compounded ten years at the blended growth rate, discounted back at 15% a year
10 Cap11.06+216%Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%
Payback Time4.01+14%Eight years of compounded free cash flow: the price at which the business pays for itself
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV0.5321-85%Earnings power value: current EPS capitalised at 9% with no growth
Zombie (liquidation)-0.4241-112%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target4.19+20%Analysts' average 12-month price target. Not in the average

Quality and financial health

GoodRx Holdings, Inc. scores 7 of 9 on the Piotroski F-score, the nine yes/no tests of profitability, leverage and efficiency on the latest annual accounts - a strong reading that passes the Sunday Scan's "6 or more" rule with room to spare. A GLS Moat score of 4.5/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are thin or negative - ROIC 2.6%, ROE 4.9%, ROA 2.2% - with debt at 0.88 times equity and a free-cash-flow yield of 12.2%.

GoodRx Holdings, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Prescription Transactions Revenue 77%, Subscription Revenue 21%, Other Revenue 3% (quarter Q2 FY2026).

Institutional ownership scores 4/10, insider activity 1/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score7 / 9ROIC2.6%
GLS Moat4.5 / 10ROE4.9%
Debt / equity0.88ROA2.2%
Free-cash-flow yield12.2%Payout ratio0%
Institutions4 / 10Insiders · Congress1 · 5 / 10

Wheel Score 62: Fair

A Wheel Score of 62 puts GoodRx Holdings, Inc. in the Fair band - below the 70 the Sunday Scan requires. Value 12/25, Health 16/20, Moat 7/15, Premium 14/20 and Stability 15/20; the weakest part is Moat (7/15).

Implied volatility is 85% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (14 of 20) because volatility this high usually comes with a reason. Chain open interest is 24,329 contracts across all expiries - enough for the wheel at normal size.

Volume runs at 1.9M shares a day on a market cap of $1.2B, with a beta of 1.69 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 15 of 20.

PartPointsFrom
Value12 / 25-2% margin of safety
Health16 / 20Piotroski 7/9
Moat7 / 15moat 4.5/10
Premium14 / 20implied volatility 85%
Stability15 / 201.9M shares/day, $1.2B cap, beta 1.69

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 3 Nov 2026 (after the close), 18 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Healthcare Information Services

The 12 companies below are the closest to GoodRx Holdings, Inc. by market cap within the Medical - Healthcare Information Services industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
OMDA
Omada Health
18.674.09-357%52Fair$1.1B
TDOC
Teladoc Health, Inc.
5.8121.97+74%45Weak$1.1B
HSTM
HealthStream, Inc.
33.7523.38-44%56Fair$1.0B
CERT
Certara, Inc.
9.668.34-16%45Weak$1.5B
OMCL
Omnicell, Inc.
35.9523.57-52%53Fair$1.6B
MDRX
Veradigm Inc.
5.00--37No options$851M
PHR
Phreesia, Inc.
10.6314.46+26%68Good$657M
SOPH
SOPHiA GENETICS S.A.
7.06--45Weak$601M
EVH
Evolent Health, Inc.
4.874.93+1%45Weak$548M
PRVA
Privia Health Group, Inc.
21.6742.94+50%45Weak$2.8B
NRC
NRC Health
21.118.64-144%47Weak$467M
CTEV
Claritev Corporation
23.86120.21+80%45Weak$404M

⚖ Compare GDRX with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about GDRX

Is GDRX undervalued right now?

Not meaningfully: at 3.51 the stock trades within a few percent of the GLS average fair value of 3.44 (1.8% above fair value, data as of 16 Oct 2026).

What is the Wheel Score of GDRX and what does it mean?

GDRX scores 62 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for GDRX?

3.44 per share as of 16 Oct 2026 - the simple average of the 8 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does GoodRx Holdings, Inc. report earnings next?

The next earnings report is due on 3 Nov 2026 (after the close), 18 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does GDRX have listed options, and how liquid are they?

Yes. The nightly snapshot found 64 listed contracts with 24,329 open interest across all expiries and implied volatility of 85% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.